FLT3 and acute myeloid leukemia: The data presented here indicate that a number of activating mutations render FLT3 insensitive to some TKI, and determination of the particular mutation expressed should be undertaken when deciding upon a FLT3 TKI regimen for AML patients with AL and other non-ITD point mutations.